GSK 269962
Biological Activity
Potent Rho kinase (ROCK) inhibitor (IC50 values are 1.6 and 4 nM for recombinant human ROCK1 and ROCK2 respectively). Displays greater than 30-fold selectivity for ROCK against a panel of serine/threonine kinases. Induces vasorelaxation in preconstricted rat aorta (IC50 = 35 nM); lowers blood pressure in a rat model of hypertension.
Licensing Information
Sold for research purposes under agreement from GlaxoSmithKline.
Compound Libraries
GSK 269962 is also offered as part of the Tocriscreen Plus. Find out more about compound libraries available from Tocris.
Technical Data
M. Wt | 570.6 |
Formula | C29H30N8O5 |
Storage | Store at +4°C |
Purity | ≥99% (HPLC) |
CAS Number | 850664-21-0 |
PubChem ID | 16095342 |
InChI Key | YOVNFNXUCOWYSG-UHFFFAOYSA-N |
Smiles | CCN(C(C4=NON=C4N)=N3)C1=C3C=NC(OC2=CC(NC(C5=CC=C(OCCN6CCOCC6)C=C5)=O)=CC=C2)=C1 |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data
Solvent | Max Conc. mg/mL | Max Conc. mM | |
---|---|---|---|
Solubility | |||
DMSO | 57.06 | 100 | |
ethanol | 5.71 | 10 with gentle warming |
Preparing Stock Solutions
The following data is based on the product molecular weight 570.6. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.75 mL | 8.76 mL | 17.53 mL |
5 mM | 0.35 mL | 1.75 mL | 3.51 mL |
10 mM | 0.18 mL | 0.88 mL | 1.75 mL |
50 mM | 0.04 mL | 0.18 mL | 0.35 mL |
Molarity Calculator
Reconstitution Calculator
Dilution Calculator
Product Datasheets
References
References are publications that support the biological activity of the product.
Doe et al (2007) Novel Rho kinase inhibitors with anti-inflammatory and vasodilatory activities. J.Pharmacol.Exp.Ther. 320 89 PMID: 17018693
Stavenger et al (2007) Discovery of aminofurazan-azabenzimidazoles as inhibitors of Rho-kinase with high kinase selectivity and antihypertensive activity. J.Med.Chem. 50 2 PMID: 17201404
If you know of a relevant reference for GSK 269962, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: GSK 269962, GSK 269962 supplier, glaxosmithkline, rock, rho, kinases, rock1, rock2, potent, selective, inhibitors, inhibits, antihypertensive, hypotensive, GSK269962, Rho-kinases, 4009, Tocris Bioscience
5 Citations for GSK 269962
Citations are publications that use Tocris products. Selected citations for GSK 269962 include:
Galea et al (2015) Planar cell polarity aligns osteoblast division in response to substrate strain. Stem Cell Res Ther 30 423 PMID: 25264362
Han et al (2016) Macrophages redirect phagocytosis by non-professional phagocytes and influence inflammation Nature 539 570 PMID: 27820945
Evron et al (2014) G Protein and β-arrestin signaling bias at the ghrelin receptor. J Biol Chem 289 33442 PMID: 25261469
Hutchinson et al (2014) Lipopolysaccharide promotes contraction of uterine myocytes via activation of Rho/ROCK signaling pathways. FASEB J 28 94 PMID: 24076962
Lotz-Jenne et al (2016) A high-content EMT screen identifies multiple receptor tyrosine kinase inhibitors with activity on TGFβ receptor. Oncotarget 7 25983 PMID: 27036020
Do you know of a great paper that uses GSK 269962 from Tocris? Please let us know.
Reviews for GSK 269962
There are currently no reviews for this product. Be the first to review GSK 269962 and earn rewards!
Have you used GSK 269962?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image